| Meirav Chovav |
Salomon Smith Barney
Best star rating is 3 stars. Click here for our methodology.
| 1st Place |
B.S., M.S., University of Rochester M.B.A., Rensselaer Polytechnic Institute. Chovav has been a biotech analyst at Salomon Smith Barney since 1992. She also has four years of laboratory experience in molecular biology and genetic engineering. Industry Outlook and Style
Biotech stocks have taken a roller-coaster ride in recent months. Although the sector is up 61% for the 12 months ending Aug. 4, the stocks peaked in February. They lost one-third of their value by April but had made up most of that until recent turbulence again sent prices lower.
|The Winners |
Favorite stock for next 12 months:
"Our current price target is $100, but Amgen is involved with litigation that we believe the company will win. Once it does so, we believe the price target could go way up. We think the case could be over by September. So we see major upside to that stock."
Rate Their Stock Picks: